Sucampo Pharmaceuticals, Inc. (SCMP)

Check out top investors' recommendation for SCMP
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
20.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Sucampo Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other novel drug technologies in the Americas, Europe, and Asia. It develops prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, as well as for other therapeutic applications. The company offers AMITIZA for the treatment of chronic idiopathic constipation in adults; chronic constipation; and irritable bowel syndrome with constipation in adult women; and RESCULA for the treatment of open-angle glaucoma and ocular hypertension. The company’s products in pipeline include AMITIZA, which has completed Phase III trail for the treatment of opioid-induced constipation in patients with chronic non-cancer pain; and is in Phase III trail for pediatric functional constipation. Its products in pipeline also comprise cobiprostone (SPI-8811), which is in phase 1 clinical development for the target indication of prevention of oral mucositis; SPI-3608 that is in Phase I trial for the treatment of spinal stenosis; and SPI-017, which is in Phase IIA trial for the treatment of peripheral arterial disease and spinal stenosis. Sucampo Pharmaceuticals, Inc. is headquartered in Bethesda, Maryland.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
David Buck Shore Capital Buy   Nov 14, '17     14.00  Nov 14, '18  N/A 
Jason Kolbert Maxim Group Buy   Nov 02, '17     23.00  Nov 02, '18  N/A 
Jason Kolbert Maxim Group Buy   Sep 11, '17     23.00  Sep 11, '18  N/A 
Jason Kolbert Maxim Group Buy   Aug 02, '17     23.00  Aug 02, '18  N/A 
Jason Kolbert Maxim Group Buy   Mar 09, '16   12.31  26.00  Mar 09, '17  -2.11% 
Ami Fadia UBS Buy   Feb 09, '16   11.45  20.00  Feb 09, '17  1.31% 
Jason Kolbert Maxim Group Buy   Jan 11, '16   14.26  25.00  Jan 11, '17  -6.38% 
Louise Chen Guggenheim Securities LLC Buy   Apr 06, '15   17.21    Apr 06, '16  -36.08% 
Ravi Mehrotra Credit Suisse Sell   Mar 02, '15   13.60    Mar 02, '16  3.75% 
Irina Rivkind Cantor Fitzgerald Buy   Feb 23, '15   15.14    Feb 23, '16  -13.08% 
Irina Rivkind Cantor Fitzgerald Buy   Jan 20, '15   15.66    Jan 20, '16  -16.28% 
Jason Kolbert Maxim Group Buy   Jan 20, '15   15.66    Jan 20, '16  -16.28% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Dec 31, '14   14.28    Dec 31, '15  24.02% 
Adeyemi Ogunkoya Cantor Fitzgerald Buy   Nov 07, '14   9.25  16.00  Nov 07, '15  88.54% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Oct 10, '14   7.13    Oct 10, '15  155.12% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Aug 22, '14   6.79    Aug 22, '15  270.40% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   May 09, '14   6.80    May 09, '15  127.21% 
Irina Rivkind Cantor Fitzgerald Buy   Nov 07, '13   6.09  10.00  Nov 07, '14  64.20% 
Irina Rivkind Cantor Fitzgerald Buy   Sep 03, '13   5.92  7.00  Sep 03, '14  18.24% 
Adeyemi Ogunkoya Cantor Fitzgerald Buy   Apr 03, '13   6.83    Apr 03, '14  2.20% 
< previous12